IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Regeneron Pharmaceuticals, Inc. v Merus N.V. [2017] APO 19
Patent:2009263082
Title:Antibody producing non-human mammals
Patent Applicant: Merus N.V.
Opponent: Regeneron Pharmaceuticals, Inc.
Delegate: Dr B. Akhurst
Decision Date: 5 May 2017
Hearing Date: 13 & 14 September 2016 in Melbourne, with additional evidence and submissions filed by the parties on 5 and 19 October 2016
Catchwords: PATENTS – section 59 opposition to grant of a patent – grounds of novelty, inventive step, utility, fair basis, clarity, and definition of the invention – novelty – a prior disclosure of a transgenic mouse model provides a clear description of a transgenic mouse that in fact falls within the scope of opposed claims – other grounds unsuccessful – costs awarded – opportunity to amend.
Representation: Counsel for the applicant: Christian Dimitriadis.
Patent attorneys for the applicant: James Cherry and Adam Denley of Freehills Patent Attorneys.
Counsel for the opponent: Ben Fitzpatrick.
Patent attorneys for the opponent: Mark Wickham and David Longmuir of Phillips Ormonde Fitzpatrick.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2009263082
Title:Antibody producing non-human mammals
Applicant: Merus N.V.
Date of Decision: 5 May 2017
DECISION
The opposition succeeds. Claims 1-3, 5-7, 9-13 and 24-26 lack novelty.
Merus N.V has 2 months from the date of this decision to propose amendments to the claims.
Costs are awarded according to Schedule 8 against Merus N.V.
REASONS FOR DECISION
Background
Merus N. V. (the applicant) filed patent application 2009263082 on 29 June 2009, via the PCT, claiming priority from application PCT/NL2008/050430 filed on 27 June 2008. Following examination, application 2009263082 was advertised as accepted on 20 March 2014.
Regeneron Pharmaceuticals, Inc. (the opponent) filed a notice of opposition on 20 June 2014 and a statement of grounds and particulars (SGP) on 22 September 2014. Evidence in support, answer and reply was completed on 22 December 2014, 2 June 2015 and 19 October 2015, respectively. The matter was heard on 13 and 14 September 2016 at IP Australia’s Melbourne Patent Examination Centre.
At the hearing, I gave the parties a period of time in which to file evidence and responding evidence on a particular point in relation to a document I had admitted into the hearing under reg 5.23. This evidence was filed on 5 October 2016 and 19 October 2016, respectively.
The Evidence
Evidence in support of the opposition consisted of declarations by:
·David Tarlinton dated 21 December 2014 (Tarlinton#1) with Exhibits DT-1 and DT-2;
·Anthony L. De Franco dated 21 December 2014 (DeFranco#1) with Exhibits ALD-1 to ALD-4; and
·Andrew Murphy dated 21 December 2014 (Murphy#1) and Annexure 1.
Evidence in answer consisted of declarations by:
·Robert Brink dated 30 April 2015 (Brink#1) with Exhibits RB-1 and RB-2;
·Robert Brink dated 2 June 2015 (Brink#2) with Exhibits RB-3 to RB-6;
·Peter Hudson dated 1 May 2015 (Hudson#1) with Exhibits PH-1 to PH-3;
·Peter Hudson dated 2 June 2015 (Hudson#2
Keep reading for free
Create a free CaseChat account to read Regeneron Pharmaceuticals, Inc. v Merus N.V and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2017] APO 19
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.